Pharmaceutical

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster (Shingles): Likelihood of Approval

LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles).

May 17, 2024 - 04:00
LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currently in Phase I for Herpes Zoster (Shingles).
Read the original article

Tags:

Previous Article

LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihoo...

Next Article

LUNA-18 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug

STAT+: FDA advisory panel signals lack of confidence in...

Oct 6, 2023

STAT+: Court allows Medicare drug price negotiation to proceed

STAT+: Court allows Medicare drug price negotiation to ...

Sep 30, 2023

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023